France’s nuclear power industry under fire

Promise to reduce nuclear output creates headache for Hollande

Barclays pays £72m fine for risk failure

Bank failed to carry out adequate checks on £1.9bn transaction, says FCA

Odd office moves reflect shifting London

Exits from traditional commercial centres such as the City fired by soaring rents

Four KPMG partners arrested in Belfast

Move is linked to HMRC investigation into suspected tax evasion

Billionaire arrest widens Petrobras probe

Esteves was face of Brazilian finance during boom years

Osborne says austerity not over yet

Chancellor insists billions must still be cut from public spending

Russia restricts Turkey food imports

Retaliation follows downing of military jet on Syrian border

Saudi counters ‘lower for longer’ mantra

Kingdom shifts message ahead of Opec meeting as investment collapses

Raspberry Pi bakes up £4 microcomputer

British start-up expands into internet of things

UK net migration rises to all-time high

ONS figures deal blow to government promise to limit numbers

logo of Slater & Gordon lawyers

Slater & Gordon shares halve on rule change

Investors desert law firm amid plans to reform UK claims industry

Comment & Analysis

Ingram Pinn illustration, Pfizer
©Ingram Pinn

Big Pharma is addicted to an illusion

Paying high prices for proven drugs and taking a hit to the balance sheet does not avoid the bill

NEW YORK, NY - AUGUST 10: Traders work on the floor of the New York Stock Exchange during the afternoon of August 10, 2015 in New York City. The Dow Jones surged over 230 points after five days of losses. (Photo by Andrew Burton/Getty Images) *** BESTPIX ***

Markets must get used to price quirks

Less capital and more technology are likely to bring more dislocation


The riff: Periods and marketing taboos

A tussle over adverts in New York shows how attitudes must change

Market-moving news and views, 24 hours a day

Sorry, Fast FT is unavailable at the moment


Enter job search